



2017 Public Report of Major League Baseball's Joint Drug Prevention and Treatment Program

This report covers the time from the beginning of the 2016-2017 off-season to the end of the 2017 post-season (the "2017 Reporting Period"). As per agreement between the Office of the Commissioner of Baseball and the Major League Baseball Players Association, the following report is specific to Players who compose 40-man rosters for Major League Baseball Clubs.

- 1) The total number of drug tests that were conducted during the 2017 Reporting Period was 10,237. Of this total number, the number of urine samples that were collected and analyzed for Performance Enhancing Substances, Stimulants and DHEA was 8,235. The number of blood samples that were collected and analyzed for the presence of human growth hormone (hGH) was 2,002.
- 2) Seven (7) adverse analytical findings were reported by the Montreal Laboratory that resulted in discipline. Five (5) were for Performance Enhancing Substances and two (2) were for Stimulants. The substances reported were as follows:

Performance Enhancing Substances (5)

Boldenone: 2

Nandrolone: 1

Selective Androgen Receptor Modulator (SARM) LGD-4033: 1

Stanozolol: 1

Stimulants (2)

Adderall: 1

D-Amphetamine: 1

- 3) 106 Therapeutic Use Exemptions were granted. The diagnoses were as follows:

Attention Deficit Disorder: 103

Azoospermia: 1

Hypertension: 1

Idiopathic Hypersomnia: 1